Document Detail


Bone healing process in critical-sized defects by rhBMP-2 using poloxamer gel and collagen sponge as carriers.
MedLine Citation:
PMID:  17923409     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The bone morphogenetic protein type 2, is an osteoinduction protein, but new carriers to improve its actions are being studied in recent researches. The objective of this study was to evaluate the poloxamer gel as potential carrier of the rhBMP-2 during the bone healing process and verify if the collagen sponge can improve this process. Fifty-six male Wistar rats were used, which were divided into two groups, considering two periods of time. Thus, each one of these groups was divided in four groups with seven animals each, according to the treatment and the defect filled by 4 microg rhBMP-2 in aqueous solution, 4 microg rhBMP-2 in aqueous solution+collagen sponge, 4 microg rhBMP-2 combined with poloxamer gel, and 4 microg rhBMP-2 combined with poloxamer gel+collagen sponge. After 2 and 4 weeks, respectively, animals were perfused and the hemi-mandibles removed for histological analysis. Statistical analysis of the data showed significant difference between all analyzed groups (p<0.01), and between the periods of time (p=0.0118). There was no interaction between the applied treatment and considered periods of time (p=0.642). Results showed that the rhBMP-2 used in this study was able to induce bone regeneration and had its action optimized when combined to the used carriers, being the bone repair time-dependent.
Authors:
João Paulo Mardegan Issa; Cássio do Nascimento; Mamie Mizusaki Iyomasa; Selma Siéssere; Simone Cecílio Hallak Regalo; Helton Luiz Aparecido Defino; Walter Sebald
Related Documents :
18265419 - Bone regenerative properties of injectable pgla-cap composite with tgf-beta1 in a rat a...
20626419 - Effects of nicotine on gene expression and osseointegration in rats.
20725979 - Evaluation of dense polylactic acid/beta-tricalcium phosphate scaffolds for bone tissue...
21728789 - Closure of persistent foramen ovale with the biostar biodegradable pfo closure device: ...
3568119 - Cellular response to ectopically implanted silk sutures and osteopetrotic bone.
12322969 - Promotion of bone formation using highly pure porous beta-tcp combined with bone marrow...
3016219 - Tissue response in dogs to dense hydroxylapatite implantation in the femur.
12037029 - The effect of replens on vaginal cytology in the treatment of postmenopausal atrophy: c...
9105919 - Enumeration of fungi in barley.
Publication Detail:
Type:  Journal Article     Date:  2007-09-04
Journal Detail:
Title:  Micron (Oxford, England : 1993)     Volume:  39     ISSN:  0968-4328     ISO Abbreviation:  Micron     Publication Date:  2008  
Date Detail:
Created Date:  2007-11-12     Completed Date:  2008-01-10     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  9312850     Medline TA:  Micron     Country:  England    
Other Details:
Languages:  eng     Pagination:  17-24     Citation Subset:  IM    
Affiliation:
Faculty of Dentistry, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. jpmissa@forp.usp.br
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Bone Morphogenetic Protein 2
Bone Morphogenetic Proteins / administration & dosage,  therapeutic use*
Collagen / administration & dosage,  therapeutic use*
Drug Carriers / therapeutic use*
Histocytochemistry
Male
Mandible / cytology
Osteogenesis / drug effects,  physiology*
Osteotomy
Poloxamer / therapeutic use*
Rats
Rats, Wistar
Recombinant Proteins / administration & dosage,  therapeutic use*
Transforming Growth Factor beta / administration & dosage,  therapeutic use*
Chemical
Reg. No./Substance:
0/Bmp2 protein, rat; 0/Bone Morphogenetic Protein 2; 0/Bone Morphogenetic Proteins; 0/Drug Carriers; 0/Recombinant Proteins; 0/Transforming Growth Factor beta; 106392-12-5/Poloxamer; 9007-34-5/Collagen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer.
Next Document:  [11C]-dimethylamine as a labeling agent for PET biomarkers.